Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study.
hepatocellular carcinoma
multi-omics data.
prognosis
tumor microenvironment
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
11
2019
accepted:
23
03
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
The tumor microenvironment (TME), as a potent and pervasive factor of tumorigenesis and tumor progression, has a profound impact on the clinical outcomes of hepatocellular carcinoma (HCC). A systematic analysis of TME factors in HCC is still lacking and urgently needed. In this retrospective analysis and multicenter validation study, a total of 987 HCC patients with RNA-seq or microarray data and the corresponding clinical information from five cohorts were included. A TME risk score was developed based on five factors (hypoxia, nucleotide, TCA cycle, T helper cells and activated CD8 T cells). We also identified various types of clinical parameters and molecular features associated with the TME risk score. The TME risk factor network depicts close associations among the factors. Our TME risk score could be a practical and reliable predictor that can stratify patients according to distinct clinical outcomes and was validated by integrating five HCC patient cohorts (HR= 2.27, 95% CI: 1.79-2.86, P<0.001). Pan-cancer analysis also suggested that the prognostic signature was an effective prognostic indicator in 9,122 patients across 30 types of cancer. Correlation analysis revealed that the TME risk score was significantly associated with tumor progression-related clinical factors and molecular factors. TME factors are perturbations in HCC patients, and these alterations are vital determinants of both clinical outcomes and biological characteristics. The TME risk score we proposed is valuable for deciphering the molecular characteristics of the TME in HCC and is an effective prognostic predictor for HCC prognosis evaluation.
Identifiants
pubmed: 32368297
doi: 10.7150/jca.41983
pii: jcav11p4145
pmc: PMC7196261
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4145-4156Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Immunity. 2014 Oct 16;41(4):518-28
pubmed: 25367569
Eur J Surg Oncol. 2018 Feb;44(2):195-208
pubmed: 29258719
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Antioxid Redox Signal. 2014 Oct 1;21(10):1516-54
pubmed: 24512032
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Rev Drug Discov. 2019 Sep;18(9):669-688
pubmed: 31363227
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Br J Cancer. 2010 Jan 19;102(2):428-35
pubmed: 20087356
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):598-603
pubmed: 24835771
Trends Cell Biol. 2015 Apr;25(4):198-213
pubmed: 25540894
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Cell Rep. 2018 Apr 3;23(1):255-269.e4
pubmed: 29617665
Sci Rep. 2017 Aug 8;7(1):7525
pubmed: 28790445
Nat Genet. 2016 May;48(5):500-9
pubmed: 27064257
Nat Rev Cancer. 2018 Jun;18(6):359-376
pubmed: 29700396
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Anal Chim Acta. 2014 Mar 28;819:108-15
pubmed: 24636418
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Mol Cancer. 2019 Aug 29;18(1):130
pubmed: 31464625
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Cancer Res. 2016 Feb 15;76(4):818-30
pubmed: 26837767
Hepatology. 2015 Jan;61(1):184-90
pubmed: 25234419
Trends Cell Biol. 2014 Aug;24(8):472-8
pubmed: 24985940
Hepatology. 2017 Jul;66(1):182-197
pubmed: 28370295
Cancer Cell. 2006 Aug;10(2):99-111
pubmed: 16904609
Clin Oncol (R Coll Radiol). 2015 Oct;27(10):547-60
pubmed: 26282471
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Immunity. 2009 May;30(5):646-55
pubmed: 19464987
BMC Bioinformatics. 2014 Jun 06;15:170
pubmed: 24902696
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hepatology. 2008 Feb;47(2):511-20
pubmed: 18161050
Mol Oncol. 2018 Jan;12(1):89-113
pubmed: 29117471
Physiol Rev. 2020 Jan 1;100(1):1-102
pubmed: 31414610
Cell Mol Biol Lett. 2018 Sep 20;23:46
pubmed: 30258464
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Semin Cancer Biol. 2017 Apr;43:74-89
pubmed: 28267587
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Urol Oncol. 2017 Sep;35(9):579-580
pubmed: 28789930
Clin Cancer Res. 2018 Aug 1;24(15):3717-3728
pubmed: 29666300
PLoS One. 2014 May 27;9(5):e96080
pubmed: 24867183